VIVUS (NAS: VVUS) , the pharma company that just started selling its new obesity drug Qsymia, may not be angling for a buyout; but it sounds like one of its shareholders, QVT Financial, thinks this is the best possible strategy.
In the following video, health-care analysts Max Macaluso and David Williamson discuss this news, and whether a buyout makes sense for the under-fire drugmaker.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies are looking to change everything. Newly-approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure that you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.
The article Should VIVUS Look for a Buyer? originally appeared on Fool.com.
David Williamson has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.